Peptides Similar to LL-37

Peptides Related to LL-37#

Several peptides share functional overlap with LL-37 in tissue repair and healing research. Below is a detailed comparison of their mechanisms, efficacy, and potential for combination use.

Thymosin Beta-4 (TB-500)#

We compared LL-37 with related peptides Thymosin beta-4/TB-500 and GHK-Cu across a common framework: human interventional efficacy (design, size, indication, endpoints, effect vs control), safety, preclinical strengths, and head-to-head data availability. Where possible, we prioritized randomized controlled trials (RCTs) and registered trial records.

Summary comparison

LL-37

• Chronic wounds: A randomized, double-blind, placebo-controlled trial in diabetic foot ulcers (≈40 participants, 4-week topical therapy) showed LL-37 significantly increased granulation index versus placebo at multiple time points, although decreases in IL‑1α, TNF‑α, and aerobic bacterial counts were not consistently different; safety was acceptable (NCT04098562). A larger multicenter Phase IIb RCT in hard-to-heal venous leg ulcers (n=148) found no overall benefit over placebo on primary healing outcomes, with a post hoc signal of improved healing parameters in the subgroup with large ulcers; safety was acceptable (NCT00382174).
• Oncology (intratumoral): A Phase 1/2 single-arm dose-finding study in melanoma (completed; n=4) established dosing and monitored antitumor immune responses; it was designed for safety/biologic activity rather than comparative efficacy (NCT02225366).
• Overall: LL-37 has human RCT evidence in chronic wounds with mixed results (positive DFU signal; neutral overall VLU cohort, possible benefit in large ulcers), and a small safety-focused melanoma study; topical administration appears well tolerated (NCT04098562, NCT00382174, NCT02225366).

Thymosin beta‑4 (TB4; “TB‑500” as a marketed fragment/name)

• Ophthalmology (dry eye): A Phase 2, double-masked, randomized trial (n=72; CAE model) of 0.1% TB4 (RGN‑259) versus vehicle did not meet pre-specified primary endpoints (inferior corneal staining, ocular discomfort at Day 29), but achieved statistically significant improvements in several secondary measures (e.g., central/superior staining, CAE discomfort); no adverse events were reported (NCT01387347). A separate randomized trial in severe dry eye (n=9) also reported improvements on signs/symptoms with acceptable safety (NCT01393132).
• Chronic wounds: Phase 2, randomized, double-blind, placebo-controlled topical trials were conducted for venous stasis ulcers and pressure ulcers (each planned n=72); records detail dose-ranging designs prioritizing safety with wound closure as secondary endpoints, but public postings provide limited efficacy outcomes (NCT00832091, NCT00382174).
• Systemic musculoskeletal claims: No robust randomized, controlled human trials support injectable/systemic TB‑500 for tendon/ligament or muscle injuries; reviews emphasize a gap between preclinical promise and absence of clinical RCTs, plus safety/quality concerns in “grey market” products (чорномидз2025"сіразона"фармакології pages 6-7, чорномидз2025"сіразона"фармакології pages 7-9).
• Overall: TB4 has multiple human interventional trials (strongest in ophthalmology) with acceptable topical safety and some secondary-efficacy signals; cutaneous wound trials exist but with sparse public efficacy reporting; systemic TB‑500 lacks controlled human evidence (NCT01387347, NCT01393132, NCT00832091, NCT00382174, чорномидз2025"сіразона"фармакології pages 6-7, чорномидз2025"сіразона"фармакології pages 7-9).

GHK‑Cu

• Dermatology/cosmetics: Summaries report small randomized, double-blind cosmetic studies with wrinkle reduction and skin-thickness/density improvements versus control comparators, but methodological detail and independent, large RCT confirmation are limited. A 2024 review stresses a surprising absence of clinical anti‑wrinkle trials using GHK‑Cu/Pal‑GHK and highlights formulation/permeation challenges; human safety datasets remain limited beyond cosmetic use.
• Wound healing: Narrative summaries mention improved ulcer closure and infection reduction with a topical GHK‑Cu formulation, but lack detailed, verifiable RCT methodology in the cited summaries; robust randomized wound‑healing trials were not identified in accessible records.
• Overall: GHK‑Cu shows extensive preclinical pro‑repair/anti‑inflammatory data and scattered cosmetic human studies, but rigorous, well‑described RCTs for wound healing or anti‑aging are scarce in accessible sources.

Head-to-head evidence

• We found no direct randomized head-to-head clinical trials comparing LL‑37 versus TB4/TB‑500 or GHK‑Cu. Available trials evaluate each peptide independently in different indications and designs.

Preclinical context (for interpretation of translational maturity)

• LL‑37: robust in vitro/in vivo antimicrobial, anti-biofilm, immunomodulatory, and pro‑reparative activity; clinical translation has proven challenging, with mixed wound RCT outcomes (workUnknownyearwhatisghkcu? pages 2-3, workUnknownyearwhatisghkcu? pages 1-2).
• TB4: strong ocular/dermal preclinical data supporting epithelial migration, laminin‑5 upregulation, anti‑inflammatory and anti‑apoptotic effects; human ophthalmic trials show secondary benefits; systemic claims remain untested in RCTs (NCT01387347, чорномидз2025"сіразона"фармакології pages 6-7).
• GHK‑Cu: extensive preclinical evidence for ECM remodeling, angiogenesis, antioxidation/anti‑inflammation and broad gene modulation; human cosmetic data are reported, but rigorous clinical trials remain limited.

Conclusions about comparative “research efficacy”

• Strength of human interventional evidence: LL‑37 has the most disease‑focused RCTs in chronic wounds with mixed efficacy signals (DFU benefit on granulation; neutral overall VLU, possible benefit in large ulcers) and acceptable safety, indicating moderate translational maturity in wound care. TB4 has several ophthalmic RCTs with secondary endpoint improvements and good safety, but limited public wound‑trial outcomes and no systemic RCTs for musculoskeletal use. GHK‑Cu’s human data are largely cosmetic with variable methodological rigor; robust RCT evidence for wound‑healing or anti‑aging remains sparse. Overall, LL‑37 and TB4 have stronger controlled human data within their respective niches than GHK‑Cu, though neither has definitive, broad phase III efficacy across indications reviewed.
• Safety: Topical LL‑37 and TB4 appear well tolerated in trials reviewed; systemic TB‑500 lacks controlled safety/efficacy data and carries theoretical oncogenic/quality concerns in unregulated markets. GHK‑Cu is widely used topically in cosmetics with limited formal safety datasets; formulation stability and permeation are practical considerations.
• Head-to-head gap: No direct comparative trials among LL‑37, TB4/TB‑500, and GHK‑Cu were identified, limiting firm rank‑ordering across indications.

Most decision-informing studies

• LL‑37 DFU RCT with positive granulation outcomes (NCT04098562); LL‑37 VLU Phase IIb RCT with neutral overall but subgroup signal (NCT00382174); LL‑37 intratumoral safety/biologic activity study (NCT02225366).
• TB4 dry‑eye Phase 2 RCT using CAE model showing secondary improvements with good safety (NCT01387347) and a small severe dry‑eye RCT (NCT01393132); topical wound Phase 2 trial designs (NCT00832091, NCT00382174).
• GHK‑Cu cosmetic RCT‑like reports and 2024 review emphasizing the lack of rigorous clinical trials.

LL-37 (Cathelicidin)#

Overview LL-37 (human cathelicidin) is a pleiotropic host-defense peptide that combines direct microbicidal activity with broad immunomodulation through GPCRs, ionotropic receptors, receptor tyrosine kinase transactivation, and context-dependent TLR modulation. Similar peptides—human β-defensins (hBD-2, hBD-3), α-defensins (HNP-1/HNP-3), cathelicidins from other species (CRAMP, BMAP-27/28), and non-cathelicidin HDPs (lactoferricin, melittin)—share overlapping mechanisms at several nodes: chemoattractant GPCRs (e.g., FPR2, CCR6, MRGPRX2), purinergic receptors (P2X7), EGFR transactivation, and convergence on MAPKs/NF-κB. Below, we summarize mechanisms and specify overlaps.

LL-37 reference profile • Receptors and transactivation: LL-37 recruits and activates immune cells primarily via FPR2/ALX; it also engages P2X7, CXCR2 in neutrophils, and MRGPRX2 in human mast cells; and transactivates EGFR in airway epithelium through ADAM-mediated triple-membrane-passing signaling (Gi-dependent contexts common). LL-37 can act from the membrane interphase, modulating receptor function allosterically and via lipid rafts, and has been suggested to interact with adhesion receptors (Mac-1) and intracellular proteins (e.g., GAPDH). • TLR modulation: LL-37 neutralizes LPS and inhibits plasma-membrane TLR4 signaling in myeloid cells, yet can promote LPS uptake to intracellular TLR4 in polarized epithelia. It chaperones nucleic acids to endosomes to facilitate TLR3 and TLR7/8/9 activation, including self-RNA/DNA complexes, thereby altering pDC and myeloid DC responses. • Signaling: Downstream pathways include Gi-coupled signaling (FPR2), PLC/PKC, PI3K/Akt, MAPKs (ERK, p38), and NF-κB, with P2X7-linked IL-1β processing; calcium influx via TRPV2 and BKCa can promote migration in some cells. • Representative cell types: neutrophils, monocytes/macrophages, epithelial cells, mast cells, dendritic cells; responses include chemotaxis, respiratory burst/NETs, cytokine/chemokine induction, barrier/wound responses.

Comparative summary by peptide

Highlights of overlaps and distinctions • FPR2/ALX axis: LL-37 and murine CRAMP share chemotactic signaling via FPR2/Fpr2 with Gi→MAPK/NF-κB outputs in neutrophils/monocytes/DCs; BMAP-27/28 are reported within cathelicidin literature to engage the same chemoattractant receptor family, supporting an overlap at the FPR2 node. • MrgX2 on mast cells: LL-37 and hBD-3 activate human mast cells via MRGPRX2, triggering degranulation and PLC→MAPKs (ERK, p38, JNK); this receptor is a shared gateway for basic amphipathic HDPs to mast-cell activation. • Purinergic receptors: LL-37 engages P2X7 to promote IL-1β processing; melittin is linked to P2X7-related activation in skin/immune contexts, indicating a shared purinergic pathway sensibility among cationic amphipathic peptides. • Chemokine-receptor chemotaxis: hBD-2 and hBD-3 mediate chemotaxis of immature DCs and memory T cells via CCR6, while LL-37 uses FPR2; LL-37 can modulate CXCR2/CXCR4 signaling in other contexts, whereas hBD-3 antagonizes CXCR4, indicating both overlap (chemokine receptor dependence) and divergence (receptor specificity and functional bias). • EGFR transactivation: LL-37 transactivates EGFR in airway/epithelial cells to drive p38/ERK-dependent responses (wound repair/barrier). Cathelicidin reviews imply similar RTK transactivation logic within the family, but explicit peptide-level evidence in the current context is strongest for LL-37. • TLR4/endotoxin control: LL-37 neutralizes LPS and inhibits TLR4-driven activation in myeloid cells, while potentially aiding LPS entry to intracellular TLR4 compartments in polarized epithelium. Lactoferricin likewise neutralizes LPS and attenuates TLR4→NF-κB signaling, providing a clear mechanistic overlap in endotoxin control. • Endosomal TLRs via nucleic-acid complexes: LL-37 uniquely forms complexes with self or microbial nucleic acids to amplify TLR3/7/8/9 signaling in pDCs and myeloid DCs; this chaperone mechanism is a hallmark for LL-37 in the current evidence set and is not attributed to the other peptides here. • Common downstream nodes: Across peptides, MAPKs (ERK, p38) and NF-κB are frequent endpoints, with Gi-dependent signaling where chemoattractant GPCRs are engaged. Mast-cell activation via MrgX2 converges on PLC/PKC and MAPKs, while purinergic P2X7 links to inflammasome-related IL-1β processing, aligning LL-37 and melittin.

Which peptides share overlapping mechanisms with LL-37? • Strong overlap: CRAMP (Fpr2/FPR2 chemotaxis; ERK/MAPK; cathelicidin family RTK transactivation logic), hBD-3 (MRGPRX2 mast-cell activation; MAPKs), lactoferricin (LPS neutralization/TLR4→NF-κB attenuation), melittin (P2X7-linked activation; NF-κB/MAPK activation). • Partial overlap: hBD-2 (CCR6-dependent chemotaxis and MAPK/NF-κB induction; shares chemokine-receptor-driven migration but uses CCR6 instead of FPR2), HNP-1 (chemotaxis and cytokine modulation with less-defined receptors in current context), BMAP-27/28 (reported cathelicidin activities overlapping endotoxin/TLR4 control and likely FPR-family engagement; peptide-specific receptor proof limited here). • LL-37-distinctive feature in present evidence: nucleic-acid chaperoning to endosomal TLRs (TLR3/7/8/9) stands out as a uniquely emphasized mechanism among compared peptides.

Limitations For some peptides (BMAP-27/28, HNP-3), receptor-level and pathway details are limited in the present context set; conclusions are therefore conservative and focused on well-supported overlaps.

Combination and Synergy#

Summary of combination evidence

• LL-37 with human beta-defensin-2 (hBD-2). A peer-reviewed review of host defense peptides in wound healing reports a synergistic effect between hBD-2 and LL-37, increasing activity against Staphylococcus aureus in vitro. Although the excerpt does not include formal synergy metrics (e.g., FIC/Bliss), it explicitly states synergy in antimicrobial assays, indicating functional complementarity between these peptides. The same source outlines complementary immune-modulatory roles of LL-37 and defensins relevant to wound repair.

• LL-37 with human beta-defensins and lysozyme. A review of AMP–antibiotic combinations cites primary work (Chen 2005) reporting synergistic effects among human beta-defensins, cathelicidin LL-37, and lysozyme against S. aureus and Escherichia coli in vitro. The passage confirms synergy qualitatively; numerical FIC/CI values are not provided in the excerpt, but the finding supports combining LL-37 with other innate peptides to enhance antibacterial activity relevant to infected wounds.

• Complementary pro-healing signaling: LL-37 plus non-coding dsRNA (DAMP). In human keratinocytes and endothelial cells, exposure to dsRNA and LL-37 together increased expression of multiple growth factors (e.g., FGF2, HBEGF, VEGFC, BTC, EGF, EREG) compared with either alone. This demonstrates a complementary, co-stimulatory effect on repair pathways, supporting the concept that LL-37 can potentiate pro-regenerative signaling when combined with other biological stimuli. Endpoints included RNA-seq, qPCR, and ELISA. No FIC-type synergy metric applies to this signaling context.

• Hybrid peptide combining LL-37 with thymosin alpha-1 (LL-37Tα1). A constructed LL-37–Tα1 hybrid showed improved LPS neutralization (LAL assay) and stronger anti-inflammatory effects than parental LL-37 in LPS-stimulated RAW264.7 macrophages, with significant reductions in NO and cytokines (TNF-α, IL-6, IL-1β), less LDH release, reduced apoptosis, and lower hemolysis. While this is an engineered hybrid rather than co-administration, it provides direct combination data demonstrating enhanced functional outcomes relative to LL-37 alone, consistent with complementary mechanisms of the parent peptides.

• Context: AMP combinations and wound healing. Reviews summarizing AMP–antibiotic combinations show frequent synergy via increased membrane permeability, biofilm disruption, and immune modulation in vivo, mechanisms also relevant to the LL-37 class; these bolster the rationale for peptide–peptide combinations though they do not add LL-37–specific peptide–peptide FIC values.

• Reference endpoints for LL-37 monotherapy. In ob/ob mouse excisional wounds, LL-37 accelerates re-epithelialization and granulation tissue formation, and in vitro promotes keratinocyte migration and signaling through MAPK/PI3K-related pathways. These endpoints contextualize potential additive or synergistic gains when combined with other peptides.

Limitations and gaps

• For LL-37 + hBD-2 and LL-37 + lysozyme/defensins, the retrieved excerpts document synergy qualitatively but do not report quantitative synergy metrics (FIC, Bliss, Loewe, or Chou–Talalay). Access to the primary Chen 2005 data would be needed to extract numeric indices.
• Evidence for LL-37 combinations with chitosan or thymosin beta-4 was not observed in the retrieved texts. The thymosin-related evidence pertains to thymosin alpha-1 in a hybrid construct, not co-administration.

Embedded summary table of combination studies and outcomes

Evidence Gaps#

Direct head-to-head comparison studies between LL-37 and related peptides are limited. Most comparisons are based on separate studies with different methodologies, making direct efficacy comparisons difficult.

Related Reading#

• LL-37 overview and research guide
• LL-37 research evidence
• LL-37 dosing protocols